top of page
Founder
Klaiupsorn P. Suddhibhaga (Ph.D.in Biochemistry), an associate professor of Siriraj Medical School, Mahidol University, has started research works on human molecular genetics since 1987.
After the success of the study of genetics of dyslipidemia (funded by a government granting agency, subsequently by a Mahidol granting Agency, and supplemented by the Faculty of Medicine, Siriraj Hospital), Dr. Klaiupsorn has established a business-level DNA laboratory since 2006.
This is the first DNA laboratory focusing mainly on genetics of heart disease and cancers in Southeast Asia and among the first commercial DNA laboratories in the world after the success of the Human Genome Project in 2003.
History
After a few decades of research experience on human genetics, in 2006, 3 years after the success of the Human Genome Project (HGP), Dr. Klaiupsorn resigned from the Faculty of Medicine, Siriraj Hospital, Mahidol University. As a standalone experienced biochemist with expertise in molecular genetic research, Dr. Klaiupsorn has made a startup and founded a business-level DNA test (genetic testing) laboratory, namely Heart Genetics Co., Ltd. The first small business with innovation and research (SBIR) on DNA business in Thailand and Southeast Asia.
The aim of our laboratory service is to provide DNA and RNA tests for a health forecast, supporting the prevention and treatment of diseases requiring genetic data for supplements, drug prescribing, and planning for specific treatment.
In 2007, National Innovation Agency (NIA), Ministry of Science and Technology, has awarded 1 of the top 10 innovations (ranked No.5th) to the laboratory, Heart Genetics Co., Ltd., founded and developed
solely by Dr. Klaiupsorn.
In January 2009, after a few years of self-funding research on cancer, a new innovation ‘Plasma DNA’ has been marketed as a personalized cancer-research test for either prevention or treatment in asymptomatic healthy individuals, cured-cancer patients, and cancer patients. [No need for tissue biopsy for DNA test]
In 2011, Dr. Klaiupsorn ’s DNA business project
has been awarded ‘The most Interesting
Technology for Investment Award’ by
The National Science and technology Development
Agency (NSTDA), Ministry of Science and Technology.
In 2013, sensitivity of the ‘Plasma DNA’ assay was improved so that we can see the cancer DNA markers in detail at the femto level (10-15 dilution) using just a few milliliter (ml) of blood sample (or body fluid). The Femto Lab© and Femto Research Group companies have been thus founded and developed for all assays involving in the personalized cancer-research test, while the assays for dyslipidemia and other genetic risk for heart disease are still under the management of Heart Genetics Co.,Ltd.
In 2017, we are marketing our new/latest innovations with cutting-edge technology, i.e., Plasma Microbiome© and Stool Microbiome©. These two tests are currently and commercially available on earth only at the Femto Lab© in Thailand. From these two tests, cancer-related viral/bacterial/fungal DNA insert in our genome can be detected and identified.
In 2017, Femto Lab© has been invited to join an event “Thailand a paradise for longevity” in Amazing Thailand Health and Wellness Showcase 2017. This event is organized by a government agency, the Tourism Authority of Thailand (TAT).
Such national awards and invitation have proven that our DNA laboratory is well recognized by the high-end healthcare business. Up till now our DNA laboratory has been the only one and the only first DNA business project in Thailand to receive the awards and support from the government agencies.
Femto Lab© of Femto Research Group is currently the only laboratory, in Asia and one of the few in the world, that offers the search for cancer cells via blood DNA and genes decoding from cancer cells in plasma (Plasma DNA/RNA or, recently named Liquid Biopsy) and body fluid/excretion. And it is the only one in the world that offers the search for cancer cells derived from DNA or genetic material of virus / bacteria / fungi inserted into the human genome.
bottom of page